Fabrication of a novel drug-resin combination device for controlled release of dextromethorphan hydrobromide

SeDeM tool-driven full factorial design for osmotic drug delivery of tramadol HCl: Formulation development, physicochemical evaluation, and in-silico PBPK modeling for predictive pharmacokinetic evaluation using GastroPlus™

The study is based on using SeDeM expert system in developing controlled-release tramadol HCl osmotic tablets and its in-silico physiologically based pharmacokinetic (PBPK) modeling for in-vivo pharmacokinetic evaluation. A Quality by Design (QbD) based approach in developing SeDEM-driven full factorial osmotic drug delivery was applied. A 2⁴ Full-factorial design was used to make the trial formulations of tramadol HCl osmotic tablets using NaCl as osmogen, Methocel K4M as rate controlling polymer, and avicel pH 101 as diluent. The preformulation characteristics of formulations (F1-F16) were determined by applying SeDeM Expert Tool. The formulation was optimized followed by in-vivo predictive pharmacokinetic assessment using PBPK “ACAT” model of GastroPlus™. The FTIR results showed no interaction among the ingredients. The index of good compressibility (ICG) values of all trial formulation blends were ≥5, suggesting direct compression is the best-suited method. Formulation F3 and F4 were optimized based on drug release at 2, 10, and 16 h with a zero-order kinetic release (r² = 0.992 and 0.994). The SEM images confirmed micropores formation on the surface of the osmotic tablet after complete drug release. F3 and F4 were also stable (shelf life 29.41 and 23.46 months). The in vivo simulation of the pharmacokinetics of the PBPK in-silico model revealed excellent relative bioavailability of F3 and F4 with reference to tramadol HCl 50 mg IR formulations. The SeDeM expert tool was best utilized to evaluate the compression characteristics of selected formulation excipients and their blends for direct compression method in designing once-daily osmotically controlled-release tramadol HCl tablets. The in-silico GastroPlus™ PBPK modeling provided a thorough pharmacokinetic assessment of the optimized formulation as an alternative to tramadol HCl in vivo studies.

Methylene Blue Release from Chitosan/Pectin and Chitosan/DNA Blend Hydrogels

Chitosan/DNA blend hydrogel (CDB) and chitosan/pectin blend hydrogel (CPB) were synthesized using an emulsion (oil-in-water) technique for the release of methylene blue (model molecule). Both hydrogels were characterized by swelling assays, Fourier transform infrared (FT-IR) spectroscopy, thermogravimetric analysis (TGA) and scanning electron microscopy (SEM), before and after the methylene blue (MB) loading. Higher swelling degrees were determined for both hydrogels in simulated gastric fluid. FT-IR spectra inferred absorption peak changes and shifts after MB loading. The TGA results confirmed changes in the polymer network degradation. The SEM images indicated low porosities on the hydrogel surfaces, with deformed structure of the CPB. Smoother and more uniform surfaces were noticed on the CDB chain after MB loading. Higher MB adsorption capacities were determined at lower initial hydrogel masses and higher initial dye concentrations. The MB adsorption mechanisms on the hydrogel networks were described by the monolayer and multilayer formation. The MB release from hydrogels was studied in simulated gastric and intestinal fluids, at 25 °C and 37 °C, with each process taking place at roughly 6 h. Higher release rates were determined in simulated gastric fluid at 25 °C. The release kinetics of MB in chitosan/DNA and chitosan/pectin matrices follows a pseudo-second-order kinetic mechanism.

Preparation and in vitro/in vivo evaluation of a clonidine hydrochloride drug-resin suspension as a sustained-release formulation

OBJECTIVE

The purpose of the present study was to prepare a clonidine hydrochloride (CH) sustained-release suspension.

METHODS

The processes involved in the drug formulation included drug loading, impregnating, and suspension preparation. Clonidine hydrochloride drug-resin complexes (CH-DRC) were prepared using the bath method and the CH-DRC impregnated before the microencapsulation process. Based on the bottom spray fluidized bed coating method, the CH microencapsulated drug-resin complexes (CH-MC) were also prepared using Surelease^® (the suspension of ethyl cellulose aqueous dispersion) as the coating material. The effects of coating (process/formulation) on the in vitro release of coating microcapsule were evaluated via single factor investigation and orthogonal design optimization. The CH-MC with optimized formulation was further dispersed in a suitable medium to obtain a sustained-release suspension. Rats were given commercial CH ordinary tablets and the CH sustained-release suspension via intragastric administration. The plasma concentration-time curve and related pharmacokinetic parameters were investigated using the non-compartment model.

RESULTS

The T_max of the CH sustained-release suspension was delayed from 2 h to 5 h compared with the CH ordinary tablets. Similarly, the C_max was reduced from 32.138 µg·mL^-1 to 18.150 µg·mL^-1 with the concentration-time curve being more gentle compared with the commercially CH ordinary tablets. After oral administration, the relative bioavailability of CH sustained-release suspension (AUC_0-24 of 137.703 µg·h·mL^-1) to its CH ordinary tablets (AUC_0-24 of 123.337 µg·h·mL^-1) was 111.65%.

CONCLUSIONS

The findings showed that the CH sustained-release suspension for oral administration was successfully formulated.